Does the USA need a national health technology assessor?

drug_money_big

In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant amount of influence over pricing negotiations in the gargantuan US market for prescription pharmaceuticals.

Founded in the mid-2000s by Steven Pearson, a physician and bioethicist, the Institute for Clinical and Economic Review (ICER) seeks to assess the cost-effectiveness of new health technologies, issuing comprehensive reports that take into account concepts such as value thresholds and the quality-adjusted life year (QALY).

Researched and prepared with participation from industry experts and with the active involvement of stakeholders attending public meetings, these reports frequently determine that a drugmaker’s recommended retail price renders the therapy non-cost effective, providing helpful guidelines on how much of a discount needs to be provided.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical